Antioxidants and Nanotechnology: Promises and Limits of Potentially Disruptive Approaches in the Treatment of Central Nervous System Diseases

被引:72
作者
Martinelli, Chiara [1 ]
Pucci, Carlotta [1 ]
Battaglini, Matteo [1 ,2 ]
Marino, Attilio [1 ]
Ciofani, Gianni [1 ]
机构
[1] Ist Italiano Tecnol, Smart Biointerfaces, Viale Rinaldo Piaggio 34, I-56025 Pisa, Italy
[2] Scuola Super Sant Anna, Biorobot Inst, Viale Rinaldo Piaggio 34, I-56025 Pisa, Italy
关键词
antioxidants; central nervous system disorders; drug delivery; nanomaterials; CERIUM OXIDE NANOPARTICLES; BLOOD-BRAIN-BARRIER; MESOPOROUS SILICA NANOPARTICLES; NANOSTRUCTURED LIPID CARRIERS; RECESSIVE SPASTIC ATAXIA; AMYOTROPHIC-LATERAL-SCLEROSIS; ISCHEMIA-REPERFUSION INJURY; INDUCED OXIDATIVE STRESS; DRUG-DELIVERY SYSTEM; MITOCHONDRIAL DYSFUNCTION;
D O I
10.1002/adhm.201901589
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Many central nervous system (CNS) diseases are still incurable and only symptomatic treatments are available. Oxidative stress is suggested to be a common hallmark, being able to cause and exacerbate the neuronal cell dysfunctions at the basis of these pathologies, such as mitochondrial impairments, accumulation of misfolded proteins, cell membrane damages, and apoptosis induction. Several antioxidant compounds are tested as potential countermeasures for CNS disorders, but their efficacy is often hindered by the loss of antioxidant properties due to enzymatic degradation, low bioavailability, poor water solubility, and insufficient blood-brain barrier crossing efficiency. To overcome the limitations of antioxidant molecules, exploitation of nanostructures, either for their delivery or with inherent antioxidant properties, is proposed. In this review, after a brief discussion concerning the role of the blood-brain barrier in the CNS and the involvement of oxidative stress in some neurodegenerative diseases, the most interesting research concerning the use of nano-antioxidants is introduced and discussed, focusing on the synthesis procedures, functionalization strategies, in vitro and in vivo tests, and on recent clinical trials.
引用
收藏
页数:28
相关论文
共 305 条
  • [21] Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: Implications for Parkinson's disease
    Berman, SB
    Hastings, TG
    [J]. JOURNAL OF NEUROCHEMISTRY, 1999, 73 (03) : 1127 - 1137
  • [22] Serum levels of antioxidant vitamins and lipid peroxidation in multiple sclerosis
    Besler, HT
    Çomoglu, S
    Okçu, Z
    [J]. NUTRITIONAL NEUROSCIENCE, 2002, 5 (03) : 215 - 220
  • [23] Ubiquitin-proteasome system and Parkinson's diseases
    Betarbet, R
    Sherer, TB
    Greenamyre, JT
    [J]. EXPERIMENTAL NEUROLOGY, 2005, 191 : S17 - S27
  • [24] Nanoparticle-Based Therapeutics for Brain Injury
    Bharadwaj, Vimala N.
    Nguyen, Duong T.
    Kodibagkar, Vikram D.
    Stabenfeldt, Sarah E.
    [J]. ADVANCED HEALTHCARE MATERIALS, 2018, 7 (01)
  • [25] Mesoporous silica nanoparticles in target drug delivery system: A review
    Bharti, Charu
    Nagaich, Upendra
    Pal, Ashok Kumar
    Gulati, Neha
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICAL INVESTIGATION, 2015, 5 (03) : 124 - 133
  • [26] Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight
    Bhat, Aashiq Hussain
    Dar, Khalid Bashir
    Anees, Suhail
    Zargar, Mohammad Afzal
    Masood, Akbar
    Sofi, Manzoor Ahmad
    Ganie, Showkat Ahmad
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2015, 74 : 101 - 110
  • [27] Antioxidant Carbon Particles Improve Cerebrovascular Dysfunction Following Traumatic Brain Injury
    Bitner, Brittany R.
    Marcano, Daniela C.
    Berlin, Jacob M.
    Fabian, Roderic H.
    Cherian, Leela
    Culver, James C.
    Dickinson, Mary E.
    Robertson, Claudia S.
    Pautler, Robia G.
    Kent, Thomas A.
    Tour, James M.
    [J]. ACS NANO, 2012, 6 (09) : 8007 - 8014
  • [28] A Role for Nanoparticles in Treating Traumatic Brain Injury
    Bony, Badrul Alam
    Kievit, Forrest M.
    [J]. PHARMACEUTICS, 2019, 11 (09)
  • [29] Autosomal recessive spastic ataxia of Charlevoix-Saguenay: An overview
    Bouhlal, Yosr
    Amouri, Rim
    El Euch-Fayeche, Ghada
    Hentati, Faycal
    [J]. PARKINSONISM & RELATED DISORDERS, 2011, 17 (06) : 418 - 422
  • [30] Toxin-induced models of Parkinson's disease
    Bové J.
    Prou D.
    Perier C.
    Przedborski S.
    [J]. NeuroRX, 2005, 2 (3): : 484 - 494